DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Foravirumab
Foravirumab
Inclusion and Exclusion Criteria for Each Key Question
(12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng Et Al
WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
Tanibirumab (CUI C3490677) Add to Cart
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
(12) United States Patent (10) Patent No.: US 8,883,146 B2 Fraunhofer Et Al
(INN) for Biological and Biotechnological Substances
INN Working Document 05.179 Update 2011
WHO Drug Information Vol 22, No
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(INN) for Biological and Biotechnological Substances
Strategies to Obtain Diverse and Specific Human Monoclonal
(12) United States Patent (10) Patent No.: US 9,677,055 B2 Jones Et Al
Passive Immunotherapy of Viral Infections: 'Super-Antibodies'
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
History and Practice: Antibodies in Infectious Diseases ADAM HEY1 1Preclinical Safety, Biologics, Novartis AG, Basel, Switzerland
Top View
WO 2U11/1 7921 a L
Wo 2010/095940 A2
Antibody-Drug Analogues
Assessment of the Evolution of Cancer Treatment Therapies
Antibody Engineering for Pursuing a Healthier Future
WO 2018/224673 Al 13 December 2018 (13.12.2018) W !P O PCT
International Nonproprietary Names for Pharmaceutical Substances (INN)
1232504 Examiner
Monoclonal Antibody Consumption Pattern in a Sponsored Tertiary-Care Healthcare System in a Developing Country: a Five-Year Study from 2013 - 2017
Tim Malawi Mai Multe
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Embase 1988 to 2014 Week 36, Ovid MEDLINE(R) In-Process
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Antiviral Therapy in Chronic Hepatitis B Viral Infection During Pregnancy
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Anticorps Monoclonaux En Infectiologie Des Nouveaux Partenaires Dans L'arsenal Thérapeutique
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Supplemental Table 1: Inclusion and Exclusion Criteria